AU2434297A - The use of 5-ht1b/1d agonists to treat ocular pain - Google Patents

The use of 5-ht1b/1d agonists to treat ocular pain

Info

Publication number
AU2434297A
AU2434297A AU24342/97A AU2434297A AU2434297A AU 2434297 A AU2434297 A AU 2434297A AU 24342/97 A AU24342/97 A AU 24342/97A AU 2434297 A AU2434297 A AU 2434297A AU 2434297 A AU2434297 A AU 2434297A
Authority
AU
Australia
Prior art keywords
ht1b
agonists
ocular pain
treat ocular
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24342/97A
Inventor
Daniel A. Gamache
Najam Sharif
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU2434297A publication Critical patent/AU2434297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
AU24342/97A 1996-05-23 1997-04-02 The use of 5-ht1b/1d agonists to treat ocular pain Abandoned AU2434297A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1822196P 1996-05-23 1996-05-23
US60018221 1996-05-23
PCT/US1997/005465 WO1997044062A1 (en) 1996-05-23 1997-04-02 The use of 5-ht1b/1d agonists to treat ocular pain

Publications (1)

Publication Number Publication Date
AU2434297A true AU2434297A (en) 1997-12-09

Family

ID=21786861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24342/97A Abandoned AU2434297A (en) 1996-05-23 1997-04-02 The use of 5-ht1b/1d agonists to treat ocular pain

Country Status (2)

Country Link
AU (1) AU2434297A (en)
WO (1) WO1997044062A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE60013126T2 (en) 1999-06-03 2005-09-08 Maxim Pharmaceuticals, Inc., San Diego OPHTHALMIC HISTAMINE-CONTAINING COMPOSITIONS AND THEIR USE
WO2001015677A2 (en) * 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
WO2003082081A2 (en) * 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103106A (en) * 1991-09-25 1998-06-15 Sanofi Elf Ethers of thienocyclopentanone oximes, their preparation and pharmaceutical compositions containing them
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211276D0 (en) * 1992-05-28 1992-07-15 Glaxo Lab Sa Pharmaceutical compositions
GB9211277D0 (en) * 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
EP0574624B1 (en) * 1992-06-17 1997-09-10 Laboratoires Glaxo Sa Pharmaceutical compositions
GB9216380D0 (en) * 1992-07-31 1992-09-16 Glaxo Group Ltd Medicaments
FR2712591B1 (en) * 1993-11-19 1996-02-09 Pf Medicament New arylpiperazines derived from indole, their preparation and their therapeutic use.

Also Published As

Publication number Publication date
WO1997044062A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
EP0815838A3 (en) External skin treatment composition
AU4520697A (en) Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
EP0784992A3 (en) Treatment device for malignant changes of tissue
AU2228297A (en) Use of isoniazid for the treatment of hyperlipoproteinemia
AU2972497A (en) Treatment of oils
AU4774597A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
AU3784999A (en) Methods for treatment of pain
AU2387097A (en) Substituted benzylamines and their use for the treatment of depression
AU6917400A (en) Use of 5-ht1b/1d agonists to treat otic pain
AU1697197A (en) Immunoconjugate for the treatment of aids
AU5056099A (en) Compounds for use in the treatment of inflammation
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU5427398A (en) Cytoperfusion of tissue specimens
HK1022267A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
AU5593398A (en) The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology
AU7106300A (en) Treatment of skin disorders
AU2434297A (en) The use of 5-ht1b/1d agonists to treat ocular pain
AU2870597A (en) Treatment of liquid
AU2068295A (en) Skin treatment composition
AU9278598A (en) Use of azole derivatives for the treatment of inflammatory skin conditions
AU3167297A (en) The use of buckminsterfullerene for treatment of neurotoxic injury
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU5699396A (en) Compositions for the treatment of skin conditions
AU4489397A (en) The use of calpain inhibitors to treat ocular neural pathology
AU2510197A (en) Solid agent for the treatment of keratinous fibres